Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › TLSA

Tiziana Life Sciences

TLSA Rare disease Lead: Phase 2 3 Biotech Distilled articles ↓ 29 filings & releases ↓ 3 verdicts ↓ 2 timing quotes ↓
ImmunologyNeurology Protein

Market cap $87.8M 127.3M shares (vendor count, Nov 7, 2026) × $0.690 close Nov 6, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-05-01

Catalyst timeline

8 trackedQuarter catalyst calendar →
  1. Intranasal foralumab MSA FDA decision~Dec 29, 2026Intranasal foralumab MSA FDA decision, ~Dec 29, 2026, material
  2. Frexalimab Sanofi readout2027Frexalimab Sanofi readout, 2027, material
  3. Intranasal foralumab Alzheimer's Ph2 readout1Q 2027Intranasal foralumab Alzheimer's Ph2 readout, 1Q 2027, notable
  4. Coya 302 ALS Ph2/3 topline2Q 2027Coya 302 ALS Ph2/3 topline, 2Q 2027, material
  5. Intranasal foralumab MSA readout~Apr 1, 2027Intranasal foralumab MSA readout, ~Apr 1, 2027, notable
  6. Intranasal foralumab ALS readout~Jul 2027Intranasal foralumab ALS readout, ~Jul 2027, notable
  7. Amlenetug MSA Ph3 readout3Q 2027Amlenetug MSA Ph3 readout, 3Q 2027, notable
  8. Foralumab composition-of-matter patents patent expiryNov 6, 2027Foralumab composition-of-matter patents patent expiry, Nov 6, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Discontinued (1)

Capital (as filed)

As stated in coverage
$3.9M cash per the update of Nov 2, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Tiziana Life Sciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-10-06 Avoid Tiziana Life Sciences (TLSA) - Scientific Deep Dive for Intranasal Foralumab and Pipeline Products Despite interesting biology and clean safety, Tiziana's Class IV evidence, near-zero cash, governance concerns (founder exit fee, affiliate advances), and expiring composition patents make it uninvestable at current terms.
  2. 2026-10-16 Avoid UPDATE: Tiziana Life Sciences (TLSA) - The Balance Sheet Finally Arrives H1 2026 interim confirms negative equity, payables 3.4x cash, management admitting inability to meet obligations, and continued affiliate advances — all three WATCH LIST conditions remain unmet.
  3. 2026-11-03 Avoid UPDATE: Tiziana Life Sciences (TLSA) - Half a Hit, Full Price Drop INFORM-MS hit PET primary at 50 µg but missed at 100 µg; science improves modestly but capital structure and governance are unchanged, all three WATCH LIST conditions remain unmet, and a dilutive raise appears imminent.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (29)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Oct 16, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)